DK3570874T3 - Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder - Google Patents

Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder Download PDF

Info

Publication number
DK3570874T3
DK3570874T3 DK18741694.6T DK18741694T DK3570874T3 DK 3570874 T3 DK3570874 T3 DK 3570874T3 DK 18741694 T DK18741694 T DK 18741694T DK 3570874 T3 DK3570874 T3 DK 3570874T3
Authority
DK
Denmark
Prior art keywords
related methods
zwitterionic polymer
insulin compositions
polymer insulin
compositions
Prior art date
Application number
DK18741694.6T
Other languages
English (en)
Inventor
Zhiqiang Cao
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Application granted granted Critical
Publication of DK3570874T3 publication Critical patent/DK3570874T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18741694.6T 2017-01-17 2018-01-17 Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder DK3570874T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447048P 2017-01-17 2017-01-17
US201762453851P 2017-02-02 2017-02-02
PCT/US2018/014038 WO2018136505A1 (en) 2017-01-17 2018-01-17 Zwitterionic polymer-insulin compositions and related methods

Publications (1)

Publication Number Publication Date
DK3570874T3 true DK3570874T3 (da) 2023-04-11

Family

ID=62909216

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18741694.6T DK3570874T3 (da) 2017-01-17 2018-01-17 Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder

Country Status (4)

Country Link
US (2) US20190365907A1 (da)
EP (1) EP3570874B1 (da)
DK (1) DK3570874T3 (da)
WO (1) WO2018136505A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230225969A1 (en) * 2020-05-20 2023-07-20 Wayne State University Zwitterionic polymer particle compositions and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2347762T3 (pl) * 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
US20110097277A1 (en) * 2005-08-25 2011-04-28 University Of Washington Particles coated with zwitterionic polymers
MA33064B1 (fr) * 2009-01-28 2012-02-01 Smartcells Inc Systemes à base de conjugués pour administration contrôlée de médicaments
WO2011057224A2 (en) * 2009-11-06 2011-05-12 University Of Washington Through Its Center For Commercialization Zwitterionic polymer bioconjugates and related methods
CN102906127A (zh) * 2009-11-06 2013-01-30 华盛顿大学商业中心 来自两性离子聚合物的自组装颗粒以及相关的方法
US20150246138A1 (en) * 2012-09-04 2015-09-03 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
MX366852B (es) * 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
EP3261626A4 (en) 2015-02-27 2018-10-03 Wayne State University Methods and compositions relating to biocompatible implants

Also Published As

Publication number Publication date
US20190365907A1 (en) 2019-12-05
EP3570874A1 (en) 2019-11-27
EP3570874B1 (en) 2023-03-08
EP3570874A4 (en) 2020-06-24
US20220125937A1 (en) 2022-04-28
WO2018136505A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
DK3607069T3 (da) Produkter og sammensætninger
DK3303396T3 (da) Antistoffer mod ox40 og anvendelser deraf
DK3322804T3 (da) Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf
DK3380124T3 (da) Konjugater omfattende selv-immolative grupper og fremgangsmåder relateret dertil
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3319428T3 (da) Herbicid sammensætning omfattende cinmethylin og imazamox
DK3189081T3 (da) Cd123-bindende midler og anvendelser deraf
DK3157552T3 (da) Syntac-polypeptider og anvendelser deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3110441T3 (da) Hidtil ukendt polysaccharid og anvendelser deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3099744T3 (da) Polymersammensætning indeholdende PLLA og PDLA
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3316951T3 (da) Eyewear and flexible elements
MA49905A (fr) Polyesteramines et polyesterquats
DK3231793T3 (da) Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf